Literature DB >> 9194280

Laparoscopic splenectomy for chronic idiopathic thrombocytopenic purpura.

W J Lee1, B R Kim.   

Abstract

Since October 1994, we have performed 15 laparoscopic splenectomies for idiopathic thrombocytopenic purpura. All the patients were women, aged 23 to 47 years. We used five ports (three 10-mm ports and two 5-mm ports) for the first eight cases, but we could save one 10-mm port after changing patient's position from supine to the right lateral kidney position. There was no case of conversion to exploratory laparotomy. The mean hospital stay was 6 days. No significant perioperative morbidity or mortality was associated with the surgery. Since undergoing laparoscopic splenectomy, 12 patients have been off steroids, two patients have been on small doses of steroids, and one patient has been on the same dose of steroid with no response. Laparoscopic splenectomy is a relatively safe and reasonable operative procedure for the patient with idiopathic thrombocytopenic purpura or normal-sized spleen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194280

Source DB:  PubMed          Journal:  Surg Laparosc Endosc        ISSN: 1051-7200


  3 in total

1.  Laparoscopic splenectomy for a giant splenic epidermoid cyst: report of a case.

Authors:  Y Sakamoto; S Yunotani; G Edakuni; M Mori; A Iyama; K Miyazaki
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  Hyuk-Chan Kwon; Chang-Hoon Moon; Young-Rak Cho; Min-Chan Kim; Kyeong-Hee Kim; Jin-Yeong Han; Young-Ho Lee; Sung-Yong Oh; Sung-Hyun Kim; Jae-Seok Kim; Hyo-Jin Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

3.  Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpura.

Authors:  Chang Moo Kang; Jae Gil Lee; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim; Yoon Woong Ko; Ji Sook Han; Yoo Hong Min
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.